AI Models Back Topical Therapy for Early Breast Cancer

Rubix LS digital‑twin modeling translates preclinical results to human trial design for Project Panacea

Rubix LS partnered with TheraSyn Bio on Project Panacea, an investigational topical gel designed for local action in early‑stage, localized breast cancer. In a four‑week preclinical study (n=20 rats), tumors in treated animals shrunk by roughly 50–60% on average, with several complete responses, and no systemic toxicity observed across routine bloodwork and organ checks. A dose–response signal was evident, with higher gel strengths achieving greater tumor control.

Our role was to build AI‑driven digital‑twin models that connect the animal results to human biology. These virtual patient models integrate transdermal absorption, breast‑tissue distribution, and tumor‑response dynamics.

The simulations predict that daily topical use can achieve therapeutic concentrations in breast tissue while keeping systemic exposure low—consistent with the local‑action profile seen in animals. We’re using these insights to inform starting dose, treatment window, and early pharmacodynamic readouts (e.g., Ki‑67) in a planned window‑of‑opportunity study prior to surgery.

Why it matters: Local, non‑invasive options tailored for early‑stage disease could complement standard care and improve day‑to‑day tolerability for some patients. Model‑informed development helps de‑risk and accelerate the path from bench to first‑in‑human testing.

Read the full data and next steps on TheraSyn Bio → TherasynbioProject Panacea: Topical Breast Cancer Gel Shows Tumor Shrinkage 

“Digital‑twin modeling helps us choose smarter starting doses, tighter observation windows, and the right tissue readouts—so we can move faster without cutting corners.”

 — Rubix LS Clinical Modeling Team

Note: Project Panacea is investigational and not approved by any regulatory authority. Preclinical and modeling results do not guarantee outcomes in humans.